BTK and cancer: Figure 9 shows the validation of the modeled TSK-BDBM50399512 by the experimental structure of Bruton's tyrosine kinase (Btk) bound to an anti-cancer drug, ibrutinib (PDB-ID: 5p9i, chain A, TM-score: 0.92, 58% sequence identity to the target) released on 24 May 2017 [32].